clinical trial · NCT06985576
Long-term Study to Evaluate Safety and Persistence of GF-CART01
GenomeFrontier Therapeutics TW Co., Ltd.·—·not yet recruiting·n = 18
DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma (FL)Primary Mediastinal Large B-Cell LymphomaHigh Grade B Cell Lymphoma
brief summary
The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.
started
May 1, 2026
primary completion
May 1, 2041
completion
May 1, 2041
last updated
Dec 18, 2025
detailed description
This comprehensive long-term follow-up study is meticulously designed to assess the safety and persistence of GF-CART01. Subjects who participated in the initial study of GF-01-01 and received treatment with GF-CART01, irrespective of their completion status, are eligible to participate in this follow-up study. The study may allow for a maximum enrollment of 18 subjects.
official title
A Long-term Follow-up Study of GF-01-01 to Evaluate the Safety and Persistence of GF-CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol